FS Development Corp - Ordinary Shares - Class A

:FSDC   3:41:42 PM EDT
10.16
-0.24 (-2.31%)
Name Changes, Mergers / Acquisitions

Gemini Therapeutics And FS Development Corp Announce Merger Agreement Creating Publicly Listed Precision Medicine Company Focused On Age-Related Macular Degeneration

Published: 10/15/2020 11:51 GMT
(FSDC) - Gemini Therapeutics and Fs Development Corp.
Announce Merger Agreement Creating Publicly Listed Precision Medicine Company Focused on Age-related Macular Degeneration.
Fs Development Corp - Total Proceeds From Transaction Are Expected to Be Approximately $216 Million.
Fs Development Corp - Current Gemini Shareholders Are Converting 100% of Their Existing Equity Interests Into Common Stock of Combined Company.
Fs Development Corp - Combined Company is Expected to Be Listed on Nasdaq.
Fs Development Corp - Leading Institutional Investors Commit $95 Million Through a Common Stock Private Investment in Public Equity.
Fs Development Corp - Upon Closing of Transaction, Company Will Be Renamed "gemini Therapeutics.
Fs Development - a Group of Investors Has Committed to Participate in Transaction Through a Common Stock Pipe of About $95 Million at $10.00 per Share.
Fs Development - Post-closing of Transaction, Meyenburg and Tananbaum Will Be Joined by Board Members From Gemini to Form 7-person Board.